Company intelligence / Profile preview
Ascletis Pharma Inc.
Hangzhou（杭州）, Zhejiang（浙江省）, 中国（China）ascletis.com ↗
- Ownership
- Public · 1672.HK
- Employees
- ~231
- Development stage
- Phase 2
01
Overview
Ascletis has demonstrated positive topline results in U.S. Phase Ib studies of its lead candidate ASC30—a first-in-class small molecule GLP‑1R agonist with both oral and subcutaneous dosing options for obesity. No serious adverse events were reported in recent trials. The company also markets antiviral drugs for hepatitis C and develops candidates across metabolic diseases and oncology
- Therapeutic areas
- OncologyEndocrinologyDermatologyGastroenterologyInfectious Diseases
- Modalities
- Small molecules (notably oral and injectable small molecule GLP‑1R agonists)antiviral agents
- Industry
- Biotech
02
Drug pipeline
32 assets31 more assets in the full pipeline.
03
Financials
- Market cap
- $607.7M
- Total revenue
- $304.1K
- Enterprise value
- $268.4M
Beyond the preview
Go deeper on Ascletis Pharma Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ascletis Pharma Inc..